Sebia a global diagnostic company, develops, manufactures and commercializes IVD tests dedicated to cancer, diabetes and hemoglobinopathies diagnosis. Sebia focuses on agarose and capillary electrophoresis and their dedicated automation, allowing a full routine workflow integration. Sebia completed its Myeloma line with HYDRASHIFT daratumumab, to be used with the Hydragel IF test to mitigate the DARZALEX interference, and a new generation sFLC assay: Sebia FLC kappa and lambda kits.